Evidence map›Paper›PMID 41399694›Full record

ArticleClinical epidemiology2025

Burden of Malignant Neoplasm of Bone and Articular Cartilage: Trends (1990-2021), Projections to 2030, and Comparison Between China and the G20 Countries (GBD 2021).

Zhongjiang Lan, Le Zhou, Yanliang Jiao, Shihu Kan, Songxiahe Zhao, Lei Chen, Yibin Du

Abstract read
In one paragraph

Article in Clinical epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhongjiang Lan *Department of Orthopedics, The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei, Anhui, People's Republic of China.ORCID 0009-0004-7043-2092
Le Zhou *Department of Oncology, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, People's Republic of China.
Yanliang JiaoDepartment of Orthopedics, The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei, Anhui, People's Republic of China.
Shihu KanDepartment of Orthopedics, The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei, Anhui, People's Republic of China.
Songxiahe ZhaoDepartment of Orthopedics, The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei, Anhui, People's Republic of China.
Lei ChenDepartment of Orthopedics, The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei, Anhui, People's Republic of China.
Yibin DuDepartment of Orthopedics, The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei, Anhui, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to compare the burden of malignant neoplasm of bone and articular cartilage (MNBAC) between China and the Group of Twenty (G20) countries from 1990 to 2021 and to project trends in China to 2030, thereby informing the development of targeted interventions. Methods: We extracted data on the incidence, prevalence, mortality, disability-adjusted life years (DALYs), and their corresponding age-standardized rates (ASRs) for MNBAC from the Global Burden of Disease (GBD) 2021 study. Trends were assessed based on the magnitude and precision of the estimates, without relying on statistical significance testing. Joinpoint regression identified periods with meaningful trend changes, expressed as the average annual percent change (AAPC). Decomposition analysis was employed to quantify the drivers of changes in incidence, prevalence, mortality, and DALYs. The Bayesian age-period-cohort (BAPC) model was used to project the ASR burden of MNBAC in China up to 2030. Results: From 1990 to 2021, the absolute number of MNBAC cases in China increased substantially. China's relative ranking among G20 countries rose dramatically: its age-standardized incidence rate (ASIR) climbed from 19th to 1st, age-standardized prevalence rate (ASPR) from 20th to 1st, age-standardized mortality rate (ASMR) from 13th to 4th, and age-standardized DALY rate (ASDR) from 16th to 6th. The MNBAC burden was consistently higher in males than females across all G20 countries. Decomposition analysis indicated that population aging and epidemiological changes were the primary drivers of the increasing burden in China, whereas population growth was the dominant factor in the G20 nations overall. Projections from the BAPC model suggest a decline in MNBAC-related ASIR, ASMR, and ASDR in China from 2022 to 2030. Conclusion: Despite a substantial increase in the MNBAC burden in China over the past three decades, our projections indicate a forthcoming decline in the ASIR, ASMR, and ASDR, which is likely attributable to sustained public health efforts. These findings underscore the necessity for continued, targeted interventions, particularly for males and high-risk age groups.

Indexed as

Chinaepidemiological trendsG20 countriesglobal burden of diseasemalignant neoplasm of bone and articular cartilageprojections

Identifiers

PMID41399694
PMCPMC12702289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.